Treasury yields surged to levels not seen since 2004, with the 30-year yield reaching its highest point in decades and the 10-year note also rising sharply. This increase signals potential market instability and reflects ongoing inflation and debt concerns in the U.S. The rise in yields has pushed mortgage rates to 7.45%, affecting borrowing costs for homes and cars. Despite these pressures, the S&P 500 is poised for its first weekly gain in three weeks, while the Dow faces continued losses.
As Treasury yields climb to heights not seen since 2004, Novo Nordisk (NVO) shows resilience with its price up 0.54% to USD 38.83 on Pluang as of Sep 25, 2026 20:02 WIB. The stock holds a market cap of $170.11 billion and a dividend yield of 4.65%, with most Pluang investors buying rather than selling, reflected by an 84% buy order activity. This contrasts with broader market concerns over rising borrowing costs and inflation pressures.
Novo Nordisk revealed a strategy to boost growth beyond its top obesity drugs Wegovy and Ozempic, facing patent expirations in the early 2030s. Despite promising a pipeline of new drugs, investors remain skeptical as Eli Lilly gains market share, esp...
Swedish drug-delivery company Nanexa signed a $1.33 billion global licensing deal with Novo Nordisk to use its PharmaShell technology for developing long-acting injectable drugs targeting obesity, type 2 diabetes, and cardiometabolic conditions. Novo...
At its Capital Markets Day on September 21, Novo Nordisk announced ambitious plans to launch more than five multi-blockbuster drugs by 2030 and achieve over DKK 150 billion in pipeline sales by 2035. CEO Maziar Doustdar emphasized prioritizing asset ...
Novo Nordisk's CEO Mike Doustdar said the Danish pharma company is open to a direct listing on the New York Stock Exchange, which would replace its current American depositary receipt (ADR) structure. However, the company is not actively pursuing thi...
Viking Therapeutics surged 26.5% after releasing positive topline results from its GLP-1/GIP agonist VK2735 maintenance dosing study in adults with obesity. The data suggest multiple effective maintenance dosing schedules, potentially improving patie...
